Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization
Arantza Vega, Teodorikez Wilfox Jiménez‐Rodriguez, R. Barranco, Joan Bartra, MC Diéguez, Inmaculada Doña, Montserrat Fernández‐Rivas, M Gandolfo-Cano, Gabriel Gastaminza‐Lasarte, E González-Mancebo, Belén de la Hoz Caballer, L Sánchez-Morillas, MJ Torres, MP Berges-Gimeno, Rosa Muñoz‐Cano
Abstract
Rapid drug desensitization has enabled first-line therapies in patients with drug hypersensitivity reactions to chemotherapeutic drugs including monoclonal antibodies. Desensitization is a safe and highly effective procedure, not only for IgE-mediated reactions, but also for those mediated by non-IgE mechanisms. The likelihood of breakthrough reactions during desensitization is low, and most are mild; in fact, moderate-to-severe reactions are infrequent. In this document, 16 allergy departments belonging to the Spanish research network ARADyAL present a review of the available scientific evidence and provide general guidelines for the diagnosis and management of drug hypersensitivity reactions to chemotherapeutic drugs and monoclonal antibodies. Emphasis is placed on the desensitization procedure.